For the longest time possible, rare and near-rare neuropsychiatric conditions have had very few treatment options. Today, many patients and their families have lost hope, are feeling hopeless and lonely. However, Zynerba Pharmaceuticals (NASDAQ: ZYNE) has produced transdermal cannabinoid therapies expected to offer solutions to these conditions.
And while announcing its Q1 2021 financial results, it is clear the company is making positive impacts. The results outline a $93.1 million in cash and cash equivalents above the $59.2 million as of December 31, 2020. Other operational highlights in the Q1 report included initiating a confirmatory pivotal Phase 3 trial of RECONNECT, a potential treatment for patients with Fragile X syndrome.
Meanwhile, the company says it has resumed screening patients for the 14-week open-label Phase 2 INSPIRE trial following the easing of COVID-19-related restrictions in Australia. It is also seeking an audience with the FDA to discuss data supporting the potential efficacy of Zygel in Autism Spectrum Disorder (ASD).
The Development Efforts on CBD vs. the Positive Effects in the Central Nervous System
Disorders originating from the nervous system attribute to the presence of Neuropsychiatric conditions. Their severe cognitive and behavioral manifestation primarily affect a person’s ability to learn, interact, work and emotionally cope with stress. Meaning they hit hard on the Central Nervous System.
Cannabinoids interact with specific receptors associated with a variety of diseases throughout the body. Their interaction produces pharmacologic effects. According to Zynerba, their development efforts on CBD are not in vain. The use of CBD has produced positive effects on the Central Nervous System. The CBD compound is non-euphoric, non-addictive, does not produce euphoric effects, and is not high on tetrahydrocannabinol (THC).
Other than that, Zynerba has demonstrated its continued commitment to providing new treatment options for patients battling certain rare neuropsychiatric diseases through increased research efforts. The goal is to advance the science of therapeutic cannabinoids by using an established pharmaceutical manufacturing process.
The Green Organic Dutchman Holdings (OTC: TGODF) Releases an Update on its Canadian Securities Exchange Listing
Post Views: 4 The Green Organic Dutchman Holdings (OTC: TGODF) is a top producer of organically-grown, premium certified marijuana, and it...
Next Green Wave Holdings Inc (OTCMKTS: NXGWF) Announces the Resignation of One of Its Directors
Post Views: 55 Next Green Wave Holdings Inc (OTCMKTS: NXGWF) recently announced that a Director had resigned from this position. The...
AFC Gamma Inc (NASDAQ: AFCG) Increases Quarterly Dividend by 13.2% per Share, and the Group Expands its Senior Secured Credit Facility with Devi Holdings, Inc. by $30 Million
Post Views: 26 AFC Gamma Inc (NASDAQ: AFCG) recently announced a dividend for the quarter ending September 30, 2021. The...
TerrAscend Corp (OTCMKTS: TRSSF) Acquisition of Gage Cannabis Receives Pre-Qualification Approval
Post Views: 53 TerrAscend Corp (OTCMKTS: TRSSF) is a leading cannabis operator based in North America that recently announced it had...
Jushi Holdings Inc (OTCMKTS: JUSHF) Opens 15th Store in Pennsylvania, Acquires Nature’s Remedy, and Announced Launch of Flower Brands
Post Views: 2 Jushi Holdings Inc (OTCMKTS: JUSHF), through its subsidiary, Franklin Bioscience – SE LLC. BEYOND / HELLO™ Colwyn...
FinCanna Capital Corp (OTCMKTS: FNNZF) Set to launch its “Big Fish” Cannabis-Based Edibles Brand
Post Views: 3 FinCanna Capital Corp (OTCMKTS: FNNZF) is an investment corporation for the United States licensed cannabis market that recently...